Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD.

J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.e3. doi: 10.1016/j.jaci.2009.09.022.

2.

T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome.

Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, Majewski M, Kyrcz-Krzemien S.

Haematologica. 2009 Sep;94(9):1236-41. doi: 10.3324/haematol.2008.005447.

3.

Hypereosinophilic syndrome: current approach to diagnosis and treatment.

Klion A.

Annu Rev Med. 2009;60:293-306. doi: 10.1146/annurev.med.60.062107.090340. Review.

PMID:
19630574
4.

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

Stein ML, Villanueva JM, Buckmeier BK, Yamada Y, Filipovich AH, Assa'ad AH, Rothenberg ME.

J Allergy Clin Immunol. 2008 Jun;121(6):1473-83, 1483.e1-4. doi: 10.1016/j.jaci.2008.02.033. Epub 2008 Apr 14.

5.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group.

N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530.

6.

Lymphocytic variant hypereosinophilic syndromes.

Roufosse F, Cogan E, Goldman M.

Immunol Allergy Clin North Am. 2007 Aug;27(3):389-413. Review.

PMID:
17868856
7.

Cell clonality in hypereosinophilic syndrome: what pathogenetic role?

Galimberti S, Ciabatti E, Ottimo F, Rossi A, Trombi L, Carulli G, Cervetti G, Matti L, Bianchi G, Petrini M.

Clin Exp Rheumatol. 2007 Jan-Feb;25(1):17-22.

PMID:
17417985
8.

'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.

Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A.

Leuk Res. 2007 May;31(5):691-4. Epub 2006 Nov 13.

PMID:
17095087
9.

IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites.

Wirnsberger G, Hebenstreit D, Posselt G, Horejs-Hoeck J, Duschl A.

Eur J Immunol. 2006 Jul;36(7):1882-91.

10.

High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid.

Kakinuma T, Wakugawa M, Nakamura K, Hino H, Matsushima K, Tamaki K.

Br J Dermatol. 2003 Feb;148(2):203-10.

PMID:
12588369
11.

Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides.

Kakinuma T, Sugaya M, Nakamura K, Kaneko F, Wakugawa M, Matsushima K, Tamaki K.

J Am Acad Dermatol. 2003 Jan;48(1):23-30.

PMID:
12522366
12.

High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome.

de Lavareille A, Roufosse F, Schmid-Grendelmeier P, Roumier AS, Schandené L, Cogan E, Simon HU, Goldman M.

J Allergy Clin Immunol. 2002 Sep;110(3):476-9.

PMID:
12209097
13.

Effectiveness of capillary electrophoresis using fluorescent-labeled primers in detecting T-cell receptor gamma gene rearrangements.

Greiner TC, Rubocki RJ.

J Mol Diagn. 2002 Aug;4(3):137-43. Erratum in: J Mol Diagn. 2003 Aug;5(3):195.

14.

Increased levels of a TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics.

Sekiya T, Yamada H, Yamaguchi M, Yamamoto K, Ishii A, Yoshie O, Sano Y, Morita A, Matsushima K, Hirai K.

Allergy. 2002 Feb;57(2):173-7.

15.

Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.

Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, Torii H, Asahina A, Onai N, Matsushima K, Tamaki K.

J Allergy Clin Immunol. 2001 Mar;107(3):535-41.

PMID:
11240957
16.

Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.

Simon HU, Plötz SG, Dummer R, Blaser K.

N Engl J Med. 1999 Oct 7;341(15):1112-20.

17.

Wells' syndrome: a pathogenic role for circulating CD4+CD7- T cells expressing interleukin-5 mRNA.

Yagi H, Tokura Y, Matsushita K, Hanaoka K, Furukawa F, Takigawa M.

Br J Dermatol. 1997 Jun;136(6):918-23.

PMID:
9217826
18.

Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia.

Simon HU, Yousefi S, Dommann-Scherrer CC, Zimmermann DR, Bauer S, Barandun J, Blaser K.

J Exp Med. 1996 Mar 1;183(3):1071-82.

19.

Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells.

Schandené L, Del Prete GF, Cogan E, Stordeur P, Crusiaux A, Kennes B, Romagnani S, Goldman M.

J Clin Invest. 1996 Jan 15;97(2):309-15.

20.

Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome.

Cogan E, Schandené L, Crusiaux A, Cochaux P, Velu T, Goldman M.

N Engl J Med. 1994 Feb 24;330(8):535-8. No abstract available.

Supplemental Content

Support Center